Glenmark
A new way for a new world

Glenmark Pharma Reports Q4 & FY25 Financial results

Highlights for FY2025

- *India business grew by 31.9% to Rs. 44,845 Mn*
- *Europe business grew by 17.6% to Rs. 28,463 Mn*
- *RoW business grew by 1.7% to Rs. 28,138 Mn*
- *EBITDA of Rs. 23,510 Mn with EBITDA margin of 17.6%*
- *Adjusted Profit After Tax (PAT)# of Rs.* 13,894 *Mn with Adjusted PAT margin# of 10.4%*

Mumbai, India, May 23, 2025: Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led, global pharmaceutical company, today announced its financial results for Q4FY25 ended March 31, 2025.

Q4FY25 Results:

- For the fourth quarter of FY 2024-25, Glenmark's consolidated revenue was at Rs. 32,562 Mn as against Rs. 30,630 Mn recording an increase of 6.3% YoY.
- EBITDA was Rs. 5,607 Mn in the quarter ended March 31, 2025, as compared to Rs. 5,043 Mn in the previous corresponding quarter, registering growth of 11.2%. EBITDA margin for the quarter was 17.2%.
- Adjusted Profit After Tax (PAT)# for the quarter ended March 31, 2025 was at Rs. 3,466 Mn with adjusted PAT margin# of 10.6%.

FY25 Results:

- For the year ended March 31, 2025, Glenmark's consolidated revenue was at Rs. 1,33,217 Mn as against Rs. 1,18,131 Mn, recording an increase of 12.8% over the previous corresponding period.
- EBITDA for the fiscal year ended March 31, 2025 stood at Rs. 23,510 Mn as against Rs. 11,953 Mn in the previous corresponding period. EBITDA margin for FY 2024-25 was at 17.6%.
- Adjusted Profit After Tax (PAT)# for the year ended March 31, 2025 was at Rs. 13,894 Mn, with adjusted PAT margin# of 10.4%.

Commenting on the results, Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd. said, "Our performance reflects the underlying resilience of our business, the strength of our diversified portfolio, and the focused execution of our strategic priorities. The Europe business has shown strong growth, and our branded businesses have delivered sustained results, supported by market expansion and a sharp therapeutic focus. As we move into FY26, we remain committed to building this momentum as we strengthen our global footprint.

We are also proud to share that our innovation-led pipeline continues to gain momentum, with Ichnos Glenmark Innovation (IGI) receiving US FDA Fast Track designation for ISB 2001 — a significant milestone in our journey towards advancing cutting-edge biologics for cancer care. This recognition marks a critical step forward in our aspiration to bring transformative therapies to patients and reinforces our commitment to being a science-led, future-ready organization."

Glenmark
A new way for a new world

India

Sales from the formulation business in India in Q4FY2025 was at Rs. 9,430 Mn as against Rs. 9,391 Mn in the previous corresponding quarter, recording growth of 0.4% YoY.

North America

North America registered revenue from the sales of finished dosage formulations of Rs. 7,146 Mn for the quarter ended Mar 31, 2025 as against revenue of Rs. 7,557 Mn for the previous corresponding quarter, recording decline of 5.4% YoY.

Asia, MEA, LATAM and RCIS Region (RoW)

For the fourth quarter of FY 2025, revenue from RoW was Rs. 7,898 Mn as against Rs. 7,528 Mn for the previous corresponding quarter, recording growth of 5% YoY.

Europe

Glenmark Europe's operations revenue for the fourth quarter of FY 2025, that was at Rs. 7,335 Mn as against Rs. 6,118 Mn, and recording growth of 20% YoY.

#Adjusted for the one-time exceptional items associated with generic Zetia® litigation along with associated legal costs and closure of manufacturing facility at La Chaux-de-Fonds, as reported in the Q4FY25 P&L statement

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and Pharmaceutical Sales, 2022; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2022. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 3 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com. You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma).

For media queries, please contact:

Swapnil Mishra | corpcomm@glenmarkpharma.com | +91 9164107444